Thiogenesis Therapeutics Corp.
Symbol:
TSXV: TTI
OTCQX: TTIPF
Market Cap:
33M
Purpose
Raise Awareness, Open Market Buying
Sector:
Biotechnology
Summary:
Thiogenesis is a clinical-stage biopharmaceutical company focused on developing sulfur-based prodrugs for serious pediatric conditions. The Company’s experienced leadership team has successfully brought several drugs to market, including major launches on NASDAQ. TTI-0102 is currently undergoing Phase 2 trials for MELAS. Additional Phase 2 studies are planned for Leigh syndrome and pediatric MASH, and a key Phase 3 trial for cystinosis has recently been announced.